WFA+-M2BP is a serum fibrosis marker, and we have previously reported its efficacy in estimating fibrosis and HCC development in viral hepatitis17–19; its utility for the prediction of fibrosis and HCC development has also been reported in NAFLD20–23. Here, LGALS3BP is linked to hepatocellular carcinoma.